Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Total Non-Current Liabilities (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 56.04% to $6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 56.04% decrease, with the full-year FY2024 number at $14.9 million, down 4.46% from a year prior.
  • Total Non-Current Liabilities was $6.7 million for Q3 2025 at Mereo BioPharma, down from $8.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $34.9 million in Q4 2021 to a low of $6.7 million in Q3 2025.
  • A 5-year average of $16.0 million and a median of $15.0 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 61.91% in 2021, then dropped 4.46% in 2024.
  • Mereo BioPharma's Total Non-Current Liabilities stood at $34.9 million in 2021, then fell by 25.42% to $26.0 million in 2022, then tumbled by 40.22% to $15.6 million in 2023, then fell by 4.46% to $14.9 million in 2024, then plummeted by 55.12% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Total Non-Current Liabilities are $6.7 million (Q3 2025), $8.1 million (Q2 2025), and $7.9 million (Q1 2025).